JP2022524880A - がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体 - Google Patents

がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体 Download PDF

Info

Publication number
JP2022524880A
JP2022524880A JP2021555569A JP2021555569A JP2022524880A JP 2022524880 A JP2022524880 A JP 2022524880A JP 2021555569 A JP2021555569 A JP 2021555569A JP 2021555569 A JP2021555569 A JP 2021555569A JP 2022524880 A JP2022524880 A JP 2022524880A
Authority
JP
Japan
Prior art keywords
group
formula
compound
compound according
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555569A
Other languages
English (en)
Japanese (ja)
Inventor
フィリップ・ウィルソン・ハワード
タイス・カイロー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1903541.9A external-priority patent/GB201903541D0/en
Priority claimed from GBGB2000121.0A external-priority patent/GB202000121D0/en
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2022524880A publication Critical patent/JP2022524880A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
JP2021555569A 2019-03-15 2020-03-13 がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体 Pending JP2022524880A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1903541.9A GB201903541D0 (en) 2019-03-15 2019-03-15 Compounds and conjugates
GB1903541.9 2019-03-15
GBGB2000121.0A GB202000121D0 (en) 2020-01-06 2020-01-06 Compounds and conjugates
GB2000121.0 2020-01-06
PCT/EP2020/056761 WO2020187721A1 (en) 2019-03-15 2020-03-13 Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
JP2022524880A true JP2022524880A (ja) 2022-05-10

Family

ID=69845376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555569A Pending JP2022524880A (ja) 2019-03-15 2020-03-13 がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体

Country Status (13)

Country Link
US (1) US20220160881A1 (es)
EP (1) EP3938372B1 (es)
JP (1) JP2022524880A (es)
KR (1) KR20210139270A (es)
CN (1) CN113631560A (es)
AU (1) AU2020242747A1 (es)
BR (1) BR112021018260A2 (es)
CA (1) CA3130174A1 (es)
IL (1) IL286326A (es)
MX (1) MX2021010477A (es)
SG (1) SG11202108900WA (es)
WO (1) WO2020187721A1 (es)
ZA (1) ZA202105931B (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK1109812T3 (da) 1998-08-27 2005-09-05 Spirogen Ltd Pyrrolobenzodiazepiner
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
EP2270010B1 (en) 2004-03-01 2012-01-25 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
DE602006011300D1 (de) 2005-04-21 2010-02-04 Spirogen Ltd Pyrrolobenzodiazepine
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
CA2683568A1 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
BR112015008238A2 (pt) * 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
KR20180019592A (ko) 2015-06-23 2018-02-26 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 벤조디아제핀 이량체, 그의 접합체, 제조법 및 용도
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
KR20190083654A (ko) 2016-11-10 2019-07-12 메디뮨 엘엘씨 Asct2에 특이적인 결합 분자 및 이의 용도
AU2018255876B2 (en) * 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates

Also Published As

Publication number Publication date
KR20210139270A (ko) 2021-11-22
MX2021010477A (es) 2021-10-01
US20220160881A1 (en) 2022-05-26
EP3938372A1 (en) 2022-01-19
BR112021018260A2 (pt) 2021-11-23
WO2020187721A1 (en) 2020-09-24
EP3938372B1 (en) 2023-10-25
CA3130174A1 (en) 2020-09-24
CN113631560A (zh) 2021-11-09
AU2020242747A1 (en) 2021-09-16
IL286326A (en) 2021-10-31
SG11202108900WA (en) 2021-09-29
ZA202105931B (en) 2024-01-31

Similar Documents

Publication Publication Date Title
KR102253480B1 (ko) 피롤로벤조디아제핀 컨쥬게이트
KR102312910B1 (ko) 피롤로벤조디아제핀 컨쥬게이트
KR102189731B1 (ko) 피롤로벤조디아제핀 컨쥬게이트
JP2021525265A (ja) ピロロベンゾジアゼピン複合体
JP2022512716A (ja) ピロロベンゾジアゼピン複合体
JP2022524880A (ja) がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体
KR20200143389A (ko) 항종양제로서 피롤로벤조디아제핀 및 그것의 콘주게이트
JP7259024B2 (ja) ピロロベンゾジアゼピン複合体
EA045942B1 (ru) Азетидобензодиазепиновые димеры и конъюгаты, содержащие их, для применения для лечения рака
TW202308697A (zh) 吡咯并苯并二氮呯共軛物
JP2021502969A (ja) ピロロベンゾジアゼピン複合体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319